Wellnex Life (ASX:WNX) received market authorization from Australia's Therapeutic Goods Administration for its new liquid paracetamol plus caffeine soft gel, the company said in a Tuesday Australian bourse filing.
The product will provide opportunities to use it in the company's own brands as well as opportunities to license it to third parties, the filing added.
Company shares rose past 3% in recent Tuesday trade.